Medulloblastoma (MB) is the most common malignant brain tumour of childhood affecting around 100 children each year in the UK. It is one of the largest contributors to cancer deaths in children with survivors often suffering therapy related long term health problems. Sadly, in around 40% of patients treated for MB the condition will recur. The majority of patients with relapsed medulloblastoma will die from their disease, as most existing treatments for relapsed MB can only prolong life.

This project will look at the clinical, pathological and genetic features of relapsed MB, which will provide essential insights into the biological mechanisms underlying disease relapse.